ARTICLE
5 February 2020

Millennium And Janssen Seek Leave From Supreme Court Of Canada In Section 8 Bortezomib Case

SB
Smart & Biggar

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
As previously reported, the Federal Court of Appeal (FCA) dismissed Millennium Pharmaceuticals and Janssen's appeal from a decision granting Teva's claim for...
Canada Intellectual Property

As previously reported, the Federal Court of Appeal (FCA) dismissed Millennium Pharmaceuticals and Janssen's appeal from a decision granting Teva's claim for compensation under section 8 of the Patented Medicines (Notice of Compliance) Regulations relating to Teva's bortezomib product (Janssen markets bortezomib as VELCADE). The FCA upheld Justice Locke's finding that Teva would not have infringed Patents Nos. 2,203,936 and 2,435,146 because their relevant claims were invalid for obviousness. On January 3, 2020, Millenium Pharmaceuticals and Janssen applied to the Supreme Court of Canada for leave to appeal (Docket No. 39007).

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More